BACKGROUND: We previously developed 2 etomidate analogs that retain etomidate's favorable hemodynamic properties but whose adrenocortical effects are reduced in duration or magnitude. Methoxycarbonyl (MOC)-etomidate is rapidly metabolized and ultrashort acting whereas (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate) does not potently inhibit 11␤hydroxylase. We hypothesized that MOC-etomidate's labile ester could be incorporated into carboetomidate to produce a new agent that possesses favorable properties individually found in each agent. We describe the synthesis and pharmacology of MOC-(R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (MOC-carboetomidate), a "soft" analog of carboetomidate. METHODS: MOC-carboetomidate's octanol:water partition coefficient was determined chromatographically and compared with those of etomidate, carboetomidate, and MOC-etomidate. MOC-carboetomidate's 50% effective concentration (EC 50 ) and 50% effective dose for loss of righting reflexes (LORR) were measured in tadpoles and rats, respectively. Its effect on ␥-aminobutyric acid A (GABA A ) receptor function was assessed using 2-microelectrode voltage clamp electrophysiological techniques and its metabolic stability was determined in pooled rat blood using high performance liquid chromatography. Its duration of action and effects on arterial blood pressure and adrenocortical function were assessed in rats. RESULTS: MOC-carboetomidate's octanol:water partition coefficient was 3300 Ϯ 280, whereas those for etomidate, carboetomidate, and MOC-etomidate were 800 Ϯ 180, 15,000 Ϯ 3700, and 190 Ϯ 25, respectively. MOC-carboetomidate's EC 50 for LORR in tadpoles was 9 Ϯ 1 M and its EC 50 for LORR in rats was 13 Ϯ 5 mg/kg. At 13 M, MOC-carboetomidate enhanced GABA A receptor currents by 400% Ϯ 100%. Its metabolic half-life in pooled rat blood was 1.3 min. The slope of a plot of the duration of LORR in rats versus the logarithm of the hypnotic dose was significantly shallower for MOC-carboetomidate than for carboetomidate (4 Ϯ 1 vs 15 Ϯ 3, respectively; P ϭ 0.0004123). At hypnotic doses, the effects of MOC-carboetomidate on arterial blood pressure and adrenocortical function were not significantly different from those of vehicle alone. CONCLUSIONS: MOC-carboetomidate is a GABA A receptor modulator with potent hypnotic activity that is more rapidly metabolized and cleared from the brain than carboetomidate, maintains hemodynamic stability similar to carboetomidate, and does not suppress adrenocortical function. (Anesth Analg 2012;115:297-304) 
to produce a single hypnotic drug that would possess advantageous properties found individually in each agent. We describe the synthesis and pharmacology of MOCcarboetomidate, a soft analog of carboetomidate.
METHODS Animals
All animal studies were conducted with the approval of the Subcommittee on Research Animal Care at the Massachusetts General Hospital, Boston, Massachusetts. Xenopus laevis tadpoles (early prelimb stage) and adult female Xenopus laevis frogs were purchased from Xenopus One (Ann Arbor, MI) and housed in our laboratory (tadpoles) or in the Massachusetts General Hospital Center for Comparative Medicine Animal Care Facility (frogs). Adult male Sprague-Dawley rats (300 to 420 g) were purchased from Charles River Laboratories (Wilmington, MA) and housed in the Massachusetts General Hospital Center for Comparative Medicine Animal Care Facility. All drugs were administered via a femoral venous catheter and all blood was drawn from a femoral venous or femoral arterial catheter. Arterial blood pressure was measured using a femoral arterial catheter. All femoral venous and arterial catheters were preimplanted by the vendor.
Synthesis of Carboetomidate and MOC-Carboetomidate
Carboetomidate was synthesized as previously described. 16 MOC-carboetomidate was synthesized from carboetomidate starting material (Fig. 2) . A solution of carboetomidate (5.85 g, 24 mmol) in MeOH (40 mL) was added to NaOH (6N, 12 mL). The resulting mixture was heated to 50°C for 24 h and then concentrated. The residue was acidified with 5N HCl and purified by silica gel column chromatography with dichloromethane/methanol to give the acid (4.4 g, yield 86%). MS [M ϩ 1] ϭ 216, 1 HNMR (CDCl 3 ): ␦ 7.23 to 7.34 (m, 3H), 7.15 to 7.18 (m, 3H), 7.05 (t, 1H, J ϭ 2 Hz), 6 .61 (q, 1H, J ϭ 7.2Hz), 6 .24 (dd, 1H, J ϭ 4 Hz, J ϭ 2.6Hz), 1.84 (d, 3H, J ϭ 7.2 Hz).
To a mixture of the acid(4.4 g, 20.5 mmol) and methyl-3-hydroxypropanoate(2.34 g, 22.6 mmol) in anhydrous dichloromethane (100 mL), dicyclohexylcarbodiimide (4.66 g, 22.6 mmol) and p-dimethylaminopyridine (2.76 g, 25.1 mmol) was added. The solution was stirred at room temperature for 60 h. The precipitate was removed by filtration, and the clear solution was applied to a silica gel column with dichloromethane/ether as eluents to give the product with purity ϳ89%. The crude product was further purified by prehigh performance liquid chromatography. The purified product was treated with HCl in dioxane to obtain MOC-carboetomidate hydrochloride as a yellow oil (3.12g 
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Octanol:Water Partition Coefficients
One mg of MOC-carboetomidate, MOC-etomidate, carboetomidate, or etomidate was added to 10 mL of water buffered with 10 mM Tris (pH 7.4) and 0.5 mL or 1 mL of octanol. The mixture was stirred overnight and then centrifuged to more fully separate the organic and aqueous phases. The relative concentrations of sedative-hypnotic in each phase (i.e., the partition coefficient) was determined by high performance liquid chromatography using a Varian Prostar system with a 4.6 ϫ 250 mm Proto 300 C18 column (NEST group, Southborough, MA) with the UV detector set at 240 nm. The mobile phase consisted of water and acetonitrile with 0.05% trifluoroacetic acid (Thermo Scientific, Rockford, IL). A linear gradient of 20% to 90% acetonitrile in water over 30 min was used with a flow rate of 1 mL/min.
Loss of Righting Reflex in Tadpoles
Groups of 5 Xenopus laevis tadpoles were placed in room temperature water buffered with 2.5 m⌴ Tris HCl (pH ϭ 7.4) containing a concentration of MOC-carboetomidate that ranged from 1 to 40 ⌴. Every 5 min, tadpoles were tipped with a flame-polished pipette until the response stabilized. A tadpole was determined to have loss of righting reflex (LORR) if it failed to right itself within 5 s after being turned supine. At the end of each study, tadpoles were returned to fresh water to ensure reversibility. Tadpoles that did not regain their righting reflexes in fresh water were excluded from the analysis. MOCcarboetomidate's 50% effective concentration (EC 50 ) for LORR was then determined from the concentration dependence of LORR using the quantal method of Waud. 17
GABA A Receptor Electrophysiology
Adult female Xenopus laevis frogs were anesthetized with 0.2% tricaine (ethyl-m-aminobenzoate) and hypothermia. Ovary lobes were then excised through a small laparotomy incision and placed in OR-2 solution (82 mm NaCl, 2 m⌴ KCl, 2 m⌴ MgCl 2 , 5 m⌴ HEPES, pH ϭ 7.5) containing collagenase 1A (1 mg/mL) for 3 h to separate oocytes from connective tissue.
Stage 4 and 5 oocytes were injected with messenger RNA encoding the ␣ 1 , ␤ 2 (or ␤ 2 M286W), and ␥ 2l subunits of the human ␥-aminobutyric acid A (GABA A ) receptor (ϳ40 ng of messenger RNA total at a subunit ratio of 1:1:2). This messenger RNA was transcribed from complementary DNA encoding for GABA A receptor ␣ 1 , ␤ 2 (or ␤ 2 M286W), and ␥ 2l subunits using the mMESSAGE mMACHINE High Yield Capped RNA Transcription Kit (Ambion, Austin, TX). Injected oocytes were incubated in ND-96 buffer solution (96 m⌴ NaCl, 2 m⌴ KCl, 1 m⌴CaCl 2 , 0.8 m⌴ MgCl 2 , 10 mm HEPES, pH ϭ 7.5) containing 50 U/mL of penicillin and 50 g/mL of streptomycin at 17°C for at least 18 h before electrophysiologic experiments.
All electrophysiologic recordings were performed using the whole cell 2-electrode voltage-clamp technique. Oocytes were placed in a 0.04-mL recording chamber and impaled with capillary glass electrodes filled with 3 ⌴ KCl and possessing open tip resistances Ͻ5 M⍀. Oocytes were then voltage clamped at -50 mV using a GeneClamp 500B amplifier (Axon Instruments, Union City, CA) and perfused with ND-96 buffer at a rate of 4 to 6 mL/min. Buffer perfusion was controlled using a 6-channel valve controller (Warner Instruments, Hamden, CT) interfaced with a Digidata 1322A data acquisition system (Axon Instruments) and driven by a Dell personal computer (Round Rock, TX). Current responses were recorded using Clampex 9.2 software (Axon Instruments) and processed using a Bessel (8-pole) low-pass filter with a cutoff at 50 Hz using Clampfit 9.2 software (Axon Instruments).
For each oocyte, the concentration of GABA that produced 5%-10% of the maximal current response (EC 5-10 GABA) was determined by measuring the peak current responses evoked by a range of GABA concentrations (in ND-96 buffer) and comparing them with the maximal peak current response evoked by 1 m⌴ GABA. The effect of MOC-carboetomidate on EC 5-10 GABA-evoked currents was then assessed by perfusing the oocyte with EC 5-10 GABA for 90 s and then measuring the control peak evoked current. After a 5-min recovery period, the oocyte was perfused with MOC-carboetomidate for 90 s and then with EC 5-10 GABA plus MOC-carboetomidate for 90 s, and the peak evoked current was measured again. After a 15-min recovery period to allow MOC-carboetomidate washout, the control experiment (i.e., no MOC-carboetomidate) was repeated to assure reversibility. The peak current response in the presence of MOC-carboetomidate was then normalized to the average peak current response of the 2 control experiments. MOC-carboetomidate-induced enhancement was quantified from the normalized current responses in the presence versus absence of carboetomidate.
LORR in Rats
Rats were restrained in a 3-inch diameter, 9-inch long acrylic chamber. The desired dose of MOC-carboetomidate or carboetomidate in dimethyl sulfoxide (DMSO) vehicle was injected through the femoral venous catheter followed by a 1-mL normal saline flush. After injection, rats were removed from the restraint device and turned supine. A rat was judged to have LORR if it failed to right itself (onto all 4 paws) after drug administration. A stopwatch was used to measure the duration of LORR, which was defined as the time from hypnotic injection until the animal spontaneously righted itself. The 50% effective dose (ED 50 ) for LORR was determined from the dose-dependence of LORR using the method of Waud. 17 In a separate study, the induction time was measured in rats by administering MOCcarboetomidate or carboetomidate (in DMSO vehicle) via the femoral venous catheter followed by a 1-mL normal saline flush, immediately removing from the restraint device and repeatedly turning them supine until they no longer spontaneously righted. The induction time was defined as the time from injection until LORR occurred.
In Vitro Metabolism in Pooled Rat Blood
Whole blood from 3 Sprague-Dawley rats (2.5 mL/rat) was drawn, immediately pooled, anticoagulated with heparin (38 U), and aliquoted into 0.2 mL samples. Each pooled blood sample was warmed at 37°C for 5 min and then sedative-hypnotic (20 mM in DMSO) was added to a final concentration of 100 M. After the desired incubation time, the metabolic reaction was quenched with 0.2 mL acetonitrile (Sigma-Aldrich, St. Louis, MO). The samples were centrifuged and the resultant plasma separated and stored at -20°C until analyzed. Sedative-hypnotic concentrations were determined in thawed plasma samples by highpressure liquid chromatography as described above for partition coefficient studies.
Rat Adrenocortical Suppression
Rats were restrained in a 3-inch diameter, 9-inch long acrylic chamber and given dexamethasone (0.2 mg/kg; American Regent, Shirley, NY) IV to suppress endogenous adrenocorticotropic hormone (ACTH) release and corticosterone production. Two hours later, blood was drawn (to measure the baseline serum corticosterone concentration), and a second dose of dexamethasone (0.2 mg/kg) was administered along with MOC-carboetomidate, etomidate, or DMSO vehicle as a control. The concentrations of MOC-carboetomidate and etomidate in DMSO were 38 and 2.9 mg/mL. Immediately after hypnotic or vehicle administration, ACTH 1-24 (25 g/kg; Sigma-Aldrich Chemical Co, St. Louis, MO) was given to stimulate corticosterone production followed by 1-mL normal saline flush. Thirty minutes after ACTH 1-24 administration, a second blood sample was drawn to measure the ACTH 1-24 -stimulated serum corticosterone concentration. Rats in all 3 groups (MOC-carboetomidate, etomidate, and vehicle control) received the same volume of DMSO (0.7 mL/kg).
All blood draws were approximately 0.4 mL in volume. Corticosterone concentrations in blood serum were determined as reported previously. Briefly, blood samples were allowed to clot at room temperature (30 to 60 min) and then centrifuged at 3,500g for 5 min. Serum was expressed from the resulting superficial fibrin clot and the sample was centrifuged again at 3,500g for 5 min. After the second centrifugation step, the clot-free serum layer was transferred to a fresh vial for final, high-speed centrifugation (16,000g, for 5min). The serum was transferred to a clean vial and frozen (-20°C) pending corticosterone measurement. After thawing and heat inactivation of corticosterone-binding globulins (65°C for 20 min), serum baseline and ACTH 1-24 -stimulated corticosterone concentrations were quantified using an enzyme-linked immunosorbent assay (Immunodiagnostic Systems Inc, Fountain Hills, AZ) and a 96-well plate reader (Molecular Devices, Sunnyvale, CA).
Hemodynamic Effects
Rats were restrained in a 3-inch diameter, 9-inch long acrylic chamber and allowed to acclimate for approximately 10 to 20 min before study. Arterial blood pressure was recorded using a Propaq Encore 206EL monitor (Welsh Allyn Inc., Skaneateles Falls, NY) every 30 s beginning 5 min before MOC-carboetomidate or DMSO vehicle administration and then for 15 min thereafter. To keep the total volume of DMSO constant at 0.7 mL/kg for all rats, the concentrations of MOC-carboetomidate in DMSO were 38 mg/mL and 76 mg/mL when given at doses of 27 mg/kg and 54 mg/kg, respectively.
Statistical Analysis
All data are reported as mean Ϯ SD unless otherwise noted. Statistical analysis and curve fitting were performed using either Prism v5.0 for the Macintosh (GraphPad Software, Inc., LaJolla, CA) or Igor Pro 6.1 (Wavemetrics, Lake Oswego, OR). P Ͻ 0.05 indicates statistical significance unless otherwise indicated. For multiple comparisons of biochemical and physiological data derived from rats, we performed a 1-way or 2-way ANOVA followed by a Tukey Multiple Comparison Test.
RESULTS
MOC-carboetomidate is viscous oil at room temperature. Its octanol:water partition coefficient was 3300 Ϯ 280, whereas those for etomidate, carboetomidate, and MOCetomidate were 800 Ϯ 180, 15,000 Ϯ 3700, and 190 Ϯ 25, respectively.
As an initial screen of MOC-carboetomidate's hypnotic activity, we assessed its ability to produce LORR in tadpoles. We found that MOC-carboetomidate increased the fraction of tadpoles that had LORR in a concentrationdependent manner and at the highest concentration studied (40 M), it produced LORR in all 10 tadpoles (Fig. 3) . This LORR was reversible as 42 of 44 tadpoles that had LORR in our studies recovered their righting reflexes when returned to fresh water. From the MOC-carboetomidate concentration-dependence of LORR, we calculated an EC 50 of 9 Ϯ 1 M.
MOC-carboetomidate also increased the fraction of rats that had LORR in a dose-dependent manner and at the highest doses studied (20 to 200 mg/kg), it produced reversible LORR in all rats. From the MOC-carboetomidate dose-response curve for LORR shown in Figure 4A , we calculated MOC-carboetomidate's ED 50 to be 13 Ϯ 5 mg/kg (n ϭ 27). For comparison, this figure also shows the carboetomidate dose-response curve for LORR in rats, which yielded an ED 50 of 7.7 Ϯ 0.8 mg/kg. Figure 4B plots the duration of LORR as a function of MOCcarboetomidate or carboetomidate dose and demonstrates that for both sedative-hypnotics, the duration of LORR Pharmacological Studies of Methoxycarbonyl-Carboetomidate increased with dose. However the slope of this relationship was significantly shallower for MOC-carboetomidate than for carboetomidate (4 Ϯ 1 vs 15 Ϯ 3, respectively; P ϭ 0. 0004123). We also determined the induction time upon administration of the 2 hypnotics at doses equal to 4ϫ their respective ED 50 values for LORR and found that they were not significantly different at 16 Ϯ 3 s (range: 10 to 18 s) for MOC-carboetomidate and 19 Ϯ 6 s (range: 11 to 27 s) for carboetomidate.
To test whether enhanced GABA A receptor function might mediate this LORR, we assessed MOC-carboetomidate's ability to increase currents elicited by an EC 5-10 GABA and mediated a 1 b 2 g 2L GABA A receptors. Figure 5 shows representative current traces obtained from a single oocyte experiment and demonstrates that MOC-carboetomidate increased such currents. At a MOC-carboetomidate concentration of 13 M, the current magnitude measured in 5 separate oocytes increased by 400% Ϯ 100%.
MOC-carboetomidate was designed as a rapidly metabolized "soft" analog of carboetomidate. We compared the metabolic stability of MOC-carboetomidate with those of carboetomidate, MOC-etomidate, and etomidate by adding each sedative-hypnotic to pooled rat blood and measuring the incubation time-dependent reduction in sedative-hypnotic concentration. Figure 6 shows the percentage of unmetabolized drug remaining as a function of incubation time in rat blood and reveals that neither carboetomidate nor etomidate was significantly metabolized even after 20 min, our longest incubation time. In contrast, MOC-carboetomidate and MOC-etomidate were metabolized in an approximately first-order fashion with metabolic half-lives of 1.3 min (95% confidence intervals 1.0 to 1.6 min) and 0.35 min (95% confidence intervals 0.22 to 0.84 min), respectively. In blood samples containing MOCcarboetomidate and MOC-etomidate (but not carboetomidate or etomidate), we also detected a higher polarity compound (as indicated by its shorter chromatographic retention time) whose concentrations increased before reaching a plateau of 0.82 min (95% confidence intervals 0.60 to 1.3 min) and 0.40 min (95% confidence intervals 0.32 to 0.54 min), respectively (data not shown). A, Methoxycarbonyl (MOC)-carboetomidate and carboetomidate dose-responses curves for LORR in rats. The curve is a fit of dose-response data to a logistic equation using the method of Waud. 17 The calculated 50% effective dose values for LORR were 13 Ϯ 4 mg/kg for MOCcarboetomidate and 7.7 Ϯ 0.8 mg/kg for carboetomidate. B, Time to righting after bolus administration of MOC-carboetomidate or carboetomidate at the indicated doses. For both drugs, the time to righting increased logarithmically with dose. However, the slope of this relationship was significantly shallower for MOCcarboetomidate than for carboetomidate (4 Ϯ 1 vs 15 Ϯ 3, respectively; P ϭ 0.0004123). The effects of MOC-carboetomidate and etomidate on adrenocortical function were compared by measuring the serum corticosterone concentrations in rats thirty minutes after simultaneous administration of ACTH 1-24 and either MOC-carboetomidate (27 mg/kg), etomidate (2 mg/kg), or DMSO vehicle alone. These doses correspond to twice their respective ED 50 values for producing LORR in rats. Baseline corticosterone concentrations before ACTH 1-24 administration were not significantly different among groups and averaged 26 Ϯ 59 ng/mL. After ACTH 1-24 administration, the average serum corticosterone concentration of rats that received etomidate was 90 Ϯ 44 ng/mL, which was significantly lower than that in rats that received DMSO vehicle (460 Ϯ 140 ng/mL; Fig. 7) . In contrast, the serum corticosterone concentration of rats that received MOCcarboetomidate was 610 Ϯ 280 ng/mL. This was significantly higher than the serum corticosterone concentration in rats that received etomidate and not significantly different from the concentration in rats that received DMSO vehicle.
To determine whether the hemodynamic stability that is characteristic of etomidate, MOC-etomidate, and carboetomidate is preserved in MOC-carboetomidate, we measured the effect of MOC-carboetomidate at doses corresponding to 2ϫ and 4ϫ their ED 50 values for LORR in rats. Figure 8 shows the change in mean arterial blood pressure after a single IV bolus of 27 mg/kg MOC-etomidate, 54 mg/kg MOC-carboetomidate, or DMSO vehicle alone. Although there was a decrease in mean arterial blood pressure in all 3 groups 30 s after injection, the pressure recovered within 1 min and was not significantly different at any time point among groups during the entire experiment.
DISCUSSION
The current study describes the synthesis and pharmacological activity of MOC-carboetomidate, an etomidate analog that combines the 2 distinct structural features of MOC-etomidate and carboetomidate into a single chemical entity. Its development was motivated by the observation that MOC-etomidate and carboetomidate individually possess pharmacological properties that could be desirable if present in a single drug. MOC-etomidate is rapidly metabolized and produces hypnosis of extremely short duration because it contains a metabolicallylabile ester moiety that renders it highly susceptible to ester hydrolysis. 15 Carboetomidate is longer-acting, but does not suppress in vivo adrenocortical function because the imidazole ring thought to be necessary for high affinity etomidate binding to 11␤-hydroxylase has been replaced with a pyrrole ring. 16 In the current studies, we tested the hypothesis that MOCetomidate's metabolically labile ester group could be added to carboetomidate to produce a new chemical entity that possessed features common to both agents (i.e., GABA A receptor modulatory ability, potent hypnotic activity, and hemodynamic stability) and the key desirable properties described above that each possesses individually.
The current studies show that MOC-carboetomidate retains the GABA A receptor modulatory ability and potent hypnotic activity that are characteristic of etomidate and the two etomidate analogs upon which its structure is based. 15, 16, 18 With single bolus injection, it also maintains hemodynamic stability similar to carboetomidate and better than propofol, although we note that the DMSO vehicle that we used to formulate MOC-carboetomidate (and carboetomidate in our previous studies) produced a brief Figure 7 . The differential effects of methoxycarbonyl (MOC)carboetomidate (27 mg/kg) and etomidate (2 mg/kg) on adrenocortical function in the rat. These doses correspond to twice the respective 50% effective dose values for loss of righting reflexes. Adrenocorticotropic hormone 1 to 24 was given simultaneously with sedative-hypnotic to stimulate corticosterone production, and serum corticosterone concentrations were measured 30 min later. Four rats were studied in each group. Average corticosterone concentrations (Ϯ SD) were 460 Ϯ 140 ng/mL in the vehicle control group, 90 Ϯ 44 ng/mL in the etomidate group, and 610 Ϯ 280 ng/mL in the MOC-carboetomidate group. *P Ͻ 0.05; **P Ͻ 0.01; NS, no significant difference. Figure 8 . The effects of methoxycarbonyl (MOC)-carboetomidate on mean arterial blood pressure in the rat. MOC-carboetomidate (27 mg/kg or 54 mg/kg) in dimethyl sulfoxide vehicle or vehicle alone was administered IV at time 0. In all 3 groups, there was a significant decrease in mean arterial blood pressure 30 s after injection. However among the 3 groups, the mean blood pressure was not significantly different at any time point during the experiment.
Pharmacological Studies of Methoxycarbonyl-Carboetomidate reduction in arterial blood pressure immediately after injection. However unlike etomidate and carboetomidate (which were not detectably metabolized in rat blood even after 20 minutes), MOC-carboetomidate was rapidly metabolized in blood. Its 1.3 min in vitro metabolic half-life, while significantly slower than that of MOC-etomidate (0.35 min), was similar to that reported for esmolol (2.27 min), 19 which also contains a metabolicallylabile ester moiety. The modestly slower metabolism of MOCcarboetomidate as compared to MOC-etomidate might be advantageous because it should reduce the quantity of drug required to maintain anesthesia while retaining sufficiently rapid elimination to produce fast recovery.
The slope of a plot of the duration of LORR versus the logarithm of the hypnotic dose depends upon the rate of drug clearance from the brain and is independent of hypnotic potency. 20, 21 We previously reported that this slope is shallower for MOC-etomidate than for etomidate, which is consistent with faster MOC-etomidate brain clearance due to more rapid metabolism. 15 This slope was also shallower for MOC-carboetomidate than for carboetomidate; however, the difference (4-fold) was not as large as we had previously measured when comparing MOCetomidate versus etomidate (10-fold). In addition, the duration of LORR was ϳ4-fold longer after administering MOC-carboetomidate than we had previously observed upon administering equihypnotic doses of MOCetomidate. 15 These results suggest that whereas MOCcarboetomidate is cleared from the brain more rapidly than carboetomidate, it is not cleared as quickly as MOCetomidate perhaps because it is metabolized more slowly.
We administered MOC-carboetomidate dissolved in the organic solvent DMSO. This is a common approach with hydrophobic drugs during preclinical development because defining an optimal IV formulation can be timeconsuming and expensive. However, it should be noted that formulation may affect the actions of very hydrophobic drugs. For example, Dutta and Ebling found that LORR occurred significantly more slowly and electroencephalographic burst suppression required higher doses when propofol was dissolved in an organic solvent (ethanol) rather than formulated as an emulsion. 22 This group subsequently measured 300-fold higher peak lung propofol concentrations in rats that received brief infusions of nonemulsified versus emulsified propofol and concluded that pulmonary uptake and release significantly slows the increase and decrease of arterial and brain concentrations of nonemulsified propofol and reduces peak brain concentrations. 23 If MOC-carboetomidate (or carboetomidate) administered in DMSO is similarly sequestered by the lung, then optimal formulation may reduce induction time and increase hypnotic potency. Alternately, it might be possible to develop less hydrophobic analogues of MOCcarboetomidate (or carboetomidate) that do not require formulation in an emulsion and have more rapid onset of action.
In conclusion, MOC-carboetomidate combines the unique structural features of MOC-etomidate and carboetomidate into a single chemical entity. It is a GABA A receptor modulator with potent hypnotic activity that is more rapidly metabolized and cleared from the brain than carboetomidate, maintains hemodynamic stability, and does not suppress adrenocortical function.
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